VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Date: 20th March, 2025

To,
BSE Limited
P. J. Towers, Dalal Street
Mumbai- 400 001

Scrip Code: 531015

Dear Sir/Madam,

Subject: Outcome of the Board Meeting - Allotment of Equity Share Warrants pursuant to Preferential Issue under the provisions of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and applicable provisions of Companies Act 2013 and the rules made thereunder, each as amended (the "Preferential Issue")

Reference: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Board of Directors of the Company at their Meeting held on i.e., 20th March, 2025 at its Registered Office approved the allotment of 1,00,25,000 warrants on a preferential basis by way of a private placement at an issue price [including the warrant subscription price (₹5 per warrant) and the warrant exercise price (₹15 per warrant)] of ₹20 each (Rupees Twenty only), upon receipt of an amount aggregating to ₹5,01,25,000 (Rupees Five Crore One Lakh Twenty Five Thousand only) at the rate of ₹5 per warrant (being 25% of the issue price per warrant) as the warrant subscription price, to the below mentioned allottees who had subscribed to the preferential issue.

Sl. No.	Name of the Allottees	Category	No. of Equity Share Warrants
1	Dinesh Dayaram Dhanak	Non-Promoter	2,50,000
2	Nitesh Niranjan Jha	Non-Promoter	5,00,000
3	Vincent Alex D'Mello	Non-Promoter	1,50,000
4	Umesh Bikhchand Bijlani	Non-Promoter	2,00,000
5	Dwarka Prasad Gattani	Non-Promoter	2,00,000
6	Sankalp Sunil Wakkar	Non-Promoter	1,25,000
7	Dinesh Muddu Kotian	Non-Promoter	14,20,000

8	Dinakara Sateesha	Non-Promoter	1,25,000
9	Deepak Pandurang Bhojane	Non-Promoter	3,00,000
10	Trupti Uday Khanapurkar	Non-Promoter	1,00,000
11	Jigna Pravinkumar Raval	Non-Promoter	1,00,000
12	I2 Pro Services Private Limited	Non-Promoter	1,00,000
13	White Saffron Grains LLP	Non-Promoter	2,00,000
14	Mega Flex Plastics Ltd	Non-Promoter	3,00,000
15	Channel Plastics Pvt Ltd	Non-Promoter	1,45,000
16	Sampati Devi Jain	Non-Promoter	2,00,000
17	Rosy Sethia	Non-Promoter	60,000
18	Deepak Tayal	Non-Promoter	1,00,000
19	Kapish Jain	Non-Promoter	1,00,000
20	Manish Grover	Non-Promoter	5,50,000
21	WCA Services Pvt Ltd	Non-Promoter	5,00,000
22	Shammi Khanna	Non-Promoter	2,50,000
23	Jugal Kishore Bhagat	Non-Promoter	13,00,000
24	Pushpa Bhaju	Non-Promoter	15,00,000
25	Hitesh Surendrakumar Loonia	Non-Promoter	2,50,000
26	Anup Shivprasad Mundhra	Non-Promoter	1,00,000
27	Yogesh Omprakash Nimodiya	Non-Promoter	1,00,000
28	Ishan Bhaiya	Non-Promoter	1,00,000
29	Vibhu Maurya	Non-Promoter	2,50,000
30	Mohit Loonia	Non-Promoter	1,50,000
31	Venu Madhava Kaparthy	Non-Promoter	1,00,000

32	Jai Prakash Singh	Non-Promoter	1,00,000
33	Mirza Sajjad Baig	Non-Promoter	1,00,000

Each of the Warrants, so allotted, is convertible into one fully paid-up equity share of face value of ₹10/- (Rupees Ten only) of the Company in accordance with the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, on payment of the balance consideration of ₹15 per warrant (being 75% of the issue price per warrant) from the Allottees at the time of allotment of equity shares pursuant to the exercise of the conversion option against each such warrant. The equity shares issued upon conversion of the warrants so issued will be listed on the BSE.

The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular on Continuous Disclosure (SEBI Circular SEBI/HO/CFD/CFD-PoD 1/P/CIR/2023/123 dated July 13, 2023), regarding the issue of equity share warrants on a preferential basis is enclosed as Annexure-A.

The meeting commenced at 11:30 P.M. and concluded at 11:45 P.M.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours faithfully,

For **Venmax Drugs and Pharmaceuticals Ltd**

Dasi Rakesh Reddy
Digitally signed by Dasi Rakesh Reddy
Date: 2025.03.21 16:17:01 +05'30'

Dasi Rakesh Reddy
Director
DIN: 07112785

Encl: As above

VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

Disclosures a required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Items for Disclosure	Description
1	Type of securities proposed to be issued	Equity share Warrants
2	Type of issuance	Preferential Issue in accordance with Chapter V of the SEBI (ICDR) Regulations and other applicable laws.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Allotment of 1,00,25,000 fully paid-up equity share warrants of face value of Rs. 10 each ("Equity Share Warrants") to proposed Investors at a price of Rs. 20/- (Rupees Twenty only) per Equity Share Warrant including premium of Rs. 10/- per Equity Share Warrant for total consideration of up to Rs. 20,05,00,000/-
4	Names of the Investors	1. Dinesh Dayaram Dhanak 2. Nitesh Niranjan Jha 3. Vincent Alex D'Mello 4. Umesh Bikhchand Bijlani 5. Dwarka Prasad Gattani 6. Sankalp Sunil Wakkar 7. Dinesh Muddu Kotian 8. Dinakara Sateesha 9. Deepak Pandurang Bhojane 10. Trupti Uday Khanapurkar 11. Jigna Pravinkumar Raval 12. I2 Pro Services Private Limited 13. White Saffron Grains LLP 14. Mega Flex Plastics Ltd 15. Channel Plastics Pvt Ltd 16. Sampati Devi Jain 17. Rosy Sethia 18. Deepak Tayal 19. Kapish Jain 20. Manish Grover 21. WCA Services Pvt Ltd 22. Shammi Khanna 23. Jugal Kishore Bhagat 24. Pushpa Bhaju 25. Hitesh Surendrakumar Loonia 26. Anup Shivprasad Mundhra 27. Yogesh Omprakash Nimodiya 28. Ishan Bhaiya 29. Vibhu Maurya

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

		30. Mohit Loonia 31. Venu Madhava Kaparthy 32. Jai Prakash Singh 33. Mirza Sajjad Baig
5	Number of Investors	33 (Thirty-three)
6	Post allotment of securities –, issue price / allotted price (in case of convertibles) i. outcome of the subscription	Upon allotment of 1,00,25,000 Equity Share Warrants there will be no change in the Paid Up Equity share capital of the Company. Bifurcation is as follows: (a) Existing Share Capital – 52,38,930 equity shares of face value Rs. 10/- per share aggregating to Rs. 5,23,89,300/- and (b) Allotment of Equity share Warrants on preferential basis on 20th March, 2025– 1,00,25,000 equity share warrants at an issue price of Rs. 20/- per Warrant, upon receipt of 25% of the issue price (i.e., Rs. 5/-) aggregating to Rs. 5,01,25,000 (Rupees Five Crore One Lakh Twenty Five Thousand only) Each of the Warrants, so allotted, is convertible into one fully paid-up equity share of face value of ₹10/- (Rupees Ten only) of the Company in accordance with the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, on payment of the balance consideration of ₹15 per warrant (being 75% of the issue price per warrant) from the Allottees at the time of allotment of equity shares pursuant to the exercise of the conversion option against each such warrant. The equity shares issued upon conversion of the warrants so issued will be listed on the BSE. Issue Price: Rs. 20/- per Equity Share Warrant including a premium of Rs. 10/- each.
7	In case of convertibles – Intimation on conversion of securities or on lapse of the tenure of the instrument	Allotment of 1,00,25,000 (One Crore Twenty Five Thousand Only) Equity Share Warrants ("Warrants") at an issue price of Rs. 20/- per Warrant with a right to the warrant holder to apply for and be allotted 1 (One) Equity Share of the face value of Rs.10/- each of the Company ("Equity Shares") within a period of 18 (Eighteen) months from the date of allotment of the Warrants.

8	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable